ArticlePharmaceutics2021
Targeted Delivery of Liposomal Temozolomide Enhanced Anti-Glioblastoma Efficacy through Ultrasound-Mediated Blood-Brain Barrier Opening.
Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Focused ultrasound-mediated blood-brain barrier opening to enhance temozolomide delivery in glioblastoma: a systematic review of preclinical and early clinical evidence.Neurosurgical review · 2026Pooled it
- The Toxic Effect and Mechanism of TMZ Combined with siHOXB9 on Glioblastoma Cells.International journal of molecular sciences · 2025Article
- Effect of Acoustic Pressure on Temozolomide-Loaded Oleic Acid-Based Liposomes and Its Safety to Brain Tissue.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Receptor-Assisted Nanotherapeutics for Overcoming the Blood-Brain Barrier.Molecular neurobiology · 2024Review
- Status Quo in the Liposome-Based Therapeutic Strategies Against Glioblastoma: "Targeting the Tumor and Tumor Microenvironment".International journal of molecular sciences · 2024Review
- Current Non-Metal Nanoparticle-Based Therapeutic Approaches for Glioblastoma Treatment.Biomedicines · 2024Review
- Microbubble-Enhanced Focused Ultrasound for Infiltrating Gliomas.Biomedicines · 2024Review
- Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma.ACS applied materials & interfaces · 2024Article
- Article
- Article
- Heparin interferes with the uptake of liposomes in glioma.International journal of pharmaceutics: X · 2023Article
- Liposomes for the Treatment of Brain Cancer-A Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Advances in Focused Ultrasound for the Treatment of Brain Tumors.Tomography (Ann Arbor, Mich.) · 2023Review
- Applications of focused ultrasound-mediated blood-brain barrier opening.Advanced drug delivery reviews · 2022Review
- Focused Delivery of Chemotherapy to Augment Surgical Management of Brain Tumors.Current oncology (Toronto, Ont.) · 2022Review
- Oxime Therapy for Brain AChE Reactivation and Neuroprotection after Organophosphate Poisoning.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Glioblastoma (GBM) is the commonest form of primary brain tumor in the central nervous system, with median survival below 15 months and only a 25% two-year survival rate for patients. One of the major clinical challenges in treating GBM is the presence of the blood-brain barrier (BBB), which greatly limits the availability of therapeutic drugs to the tumor. Ultrasound-mediated BBB opening provides a promising approach to help deliver drugs to brain tumors. The use of temozolomide (TMZ) in the clinical treatment of GBM has been shown to be able to increase survival in patients with GBM, but this improvement is still trivial. In this study, we developed a liposomal temozolomide formulation (TMZ-lipo) and locally delivered these nanoparticles into GBM through ultrasound-mediated BBB opening technology, significantly suppressing tumor growth and prolonging tumor-bearing animal survival. No significant side effects were observed in comparison with control rats. Our study provides a novel strategy to improve the efficacy of TMZ against GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.